> Research summary — not medical advice. This page synthesizes published research on a mechanism-level intervention. It is not a clinical recommendation. Consult a qualified healthcare provider before making any changes to diet, supplementation, or treatment.
Mechanism
Ferrichrome is a cyclic hydroxamate siderophore produced by certain Lactobacillus strains. It binds extracellular iron with high affinity, restricting iron availability in the tumor microenvironment. Ferrichrome activates the JNK signaling pathway, triggering apoptosis selectively in pancreatic cancer cells.
Rationale
Pancreatic ductal adenocarcinoma (PDAC) cells exhibit elevated iron demand to sustain proliferation. By deploying ferrichrome-producing probiotics, the intervention exploits the metal dependency as an Achilles' heel (Primitive 4) through siderophore competition (Primitive 8) — starving cancer cells of iron while simultaneously inducing programmed cell death.
Evidence Status
- In vitro: Ferrichrome induces apoptosis in cancer cell lines at concentrations achievable by probiotic colonization.
- Animal model: Preliminary data in murine PDAC models shows tumor growth inhibition.
- Clinical: No human trials yet.
Open Questions
- Optimal Lactobacillus strain selection for maximal ferrichrome production in the GI tract.
- Whether ferrichrome reaches effective concentrations at the pancreatic tumor site.
- Interaction with conventional chemotherapy regimens.
—-
> Educational content, not medical advice. This page describes mechanisms by which the intervention interacts with the microbiome and metal ecology. It is not a treatment recommendation. Clinical decisions about any intervention should be made with a qualified healthcare practitioner who knows your individual history.